Poxel S.A. (OTCMKTS:PXXLF – Get Free Report)’s share price rose 28.4% on Monday . The company traded as high as $0.70 and last traded at $0.70. Approximately 100 shares traded hands during mid-day trading, The stock had previously closed at $0.55.
Poxel Stock Performance
The firm has a fifty day moving average of $0.70 and a 200-day moving average of $0.70.
Poxel Company Profile
Poxel SA, a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan.
Further Reading
- Five stocks we like better than Poxel
- 3 Tickers Leading a Meme Stock Revival
- Rocket Lab is the Right Stock for the Right Time
- Basic Materials Stocks Investing
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- Top Biotech Stocks: Exploring Innovation Opportunities
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Poxel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poxel and related companies with MarketBeat.com's FREE daily email newsletter.
